British pharmaceutical group GSK said on Tuesday that it had agreed to buy Nuvalent, a Boston-based company focused on cancer treatments, for $10.6 billion.
“The deal includes three lung cancer therapies currently in their testing phase,” GSK said in a statement.
“Two of the treatments are potential best-in-class assets that could launch this year if approved by US regulators,” GSK chief executive Luke Miels said.
GSK said again that it could complete the deal in 2026, which may allow it to launch the two late-stage drugs, zidesamtinib and neladalkib, before the end of 2026 subject to approvals.
“GSK’s proven track record, infrastructure, and expertise will support the successful commercialisation of zidesamtinib and neladalkib, and accelerate the advancement of our broader discovery pipeline,” Nuvalent CEO James Porter said in the statement.
The pharmaceutical industry has faced turbulence from tariff threats made by US President Donald Trump in 2025, aimed at encouraging investment in the United States and reducing drug prices.
GSK, along with other non-US pharmaceutical giants, agreed in December to lower the cost of its prescription medicines for American patients in exchange for tariff exemptions for three years.
Miels took the helm at GSK in January, replacing Emma Walmley after almost nine years as CEO. Miels was previously the group’s chief commercial officer.
